KOCH KEVIN
President and CEO
KOCH KEVIN has filed 1 SEC Form 4 filing (5 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, KOCH KEVIN is listed as President and CEO at Edgewise Therapeutics, Inc. Inside the rolling window, KOCH KEVIN reported no open-market purchases and 1 open-market sale totaling $785K in EWTX.
Companies traded
Other insiders at EWTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$785K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has KOCH KEVIN made?
KOCH KEVIN has filed 1 SEC Form 4 filing (5 transaction rows) across 1 company since 2026.
Which companies does KOCH KEVIN trade?
KOCH KEVIN has filed SEC Form 4 disclosures for 1 company, including EWTX.
When was KOCH KEVIN's most recent SEC Form 4 filing?
KOCH KEVIN's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is KOCH KEVIN's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, KOCH KEVIN is listed as President and CEO.
What is KOCH KEVIN's total buy and sell value in the current window?
Inside the rolling retention window, KOCH KEVIN bought $0 and sold $785K based on SEC Form 4 filings.
What was KOCH KEVIN's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 17,971 EWTX shares on 2026-08-12, worth $785K, per SEC Form 4 filings.